clinical trial · NCT06671496
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
Takeda·phase3·recruiting·n = 600
Psoriatic ArthritisZasocitinibPlacebo
brief summary
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments. The participants will be treated with either zasocitinib, or placebo. Participants will be in the study for up to 60 weeks.
started
Mar 10, 2025
primary completion
May 18, 2027
completion
Jan 26, 2028
last updated
Apr 6, 2026
official title
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol